What is the current reimbursement rate of Crizotinib by medical insurance?

Crizotinib, as an important targeted drug for the treatment of certain lung cancer patients, has been successfully launched in China and included in the medical insurance catalog. Being included in medical insurance means that patients can enjoy a certain proportion of cost reimbursement when using crizotinib, reducing the financial burden of treatment. Although the specific medical insurance reimbursement ratio will vary depending on regional policies, in general, patients can reimburse about 50% to 70% of the cost of drugs. For specific reimbursement details, patients should consult their local hospital pharmacy or medical insurance department to obtain accurate information.

Currently, crizotinib is available in the domestic market in two specifications: 250mg 60 tablets and 200mg 60 tablets. Each box usually sells for more than 10,000 yuan. Due to the high price, medical insurance support is crucial for patients. Through medical insurance reimbursement, the actual costs paid by patients will be significantly reduced, making this original drug more widely used in clinical applications. At the same time, medical insurance coverage also encourages patients to adhere to long-term treatment, thereby obtaining better treatment results.

In overseas markets, the original drug of crizotinib is also expensive, with each box usually selling for more than RMB 10,000. The price may fluctuate due to exchange rate fluctuations. Faced with high costs, some patients choose overseas generic drugs as an alternative. The efficacy of these generic drugs is basically the same as that of the original drugs, but the price is obviously affordable, which can effectively alleviate the financial pressure of patients.

Take the generic crizotinib drug produced by Lucius Pharmaceutical Factory in Laos as an example.250mg*60The price of the tablet size is only about 1,000 yuan, which is much lower than the selling price of the original drug. This not only provides patients with more choices, but also promotes the popularization and rational use of drugs. In short, with the inclusion of medical insurance and the emergence of generic drugs, the accessibility of crizotinib has been greatly improved, and the treatment burden on patients has been reduced.

Reference materials:https://go.drugbank.com/drugs/DB08865